rivaroxaban


Also found in: Medical, Wikipedia.
Related to rivaroxaban: Apixaban, Pradaxa, Dabigatran
Translations

rivaroxaban

n rivaroxabán m
References in periodicals archive ?
The real world insights from XALIA confirm the positive benefit-risk profile of rivaroxaban for the treatment of deep vein thrombosis that was established in the Phase III EINSTEIN DVT study, endorsing that these pivotal data for rivaroxaban can be translated to the patients physicians typically see in everyday clinical practice.
First of Nine Studies, Examining the Ability of Rivaroxaban to Reduce the Burden of Cancer-Associated Blood Clots, Presented at ASH Annual Meeting
com/research/fqmpx6/investigation) has announced the addition of the "Investigation Report on China Rivaroxaban Market, 2010-2019" report to their offering.
The patient was taking 20 mg of rivaroxaban and 80 mg of aspirin daily.
Rivaroxaban (Xarelto; Bayer Healthcare AG, https://www.
I hope that I can pronounce them properly - they are dabigatran, rivaroxaban and apixaban.
Cardiff and Vale Assistant Coroner Christopher Woolley criticised medical staff for failing to follow operation notes, which recommended Mrs Wise follow a prescription of blood-thinning medication Rivaroxaban.
The RE-LY trial was followed in 2011 by the ROCKET-AF trial, validating the use of rivaroxaban versus warfarin in NVAF.
Rivaroxaban is an oral direct factor Xa inhibitor with a competitive and reversible binding effect to factor Xa.
In this issue of Clinical Chemistry, Helin and colleagues report their findings when normal pooled plasmas, spiked with dabigatran (the active metabolite of dabigatran etexilate, a DTI), or rivaroxaban (a DFXaI) were sent to laboratories participating in a European external quality assessment program (3).
The recommendation by the CHMP to approve rivaroxaban for this additional use is an important milestone towards improved patient management in the treatment of pulmonary embolism,' said Dr.
The submissions are supported by data from the global EINSTEIN program, which includes two Phase 3 studies evaluating the safety and efficacy of rivaroxaban in the treatment of patients with acute symptomatic DVT or PE and the prevention of recurrent events in these patients.